Galmed Pharmaceuticals Sets Shareholder Meeting for August 14

Ticker: GLMD · Form: 6-K · Filed: Jul 24, 2025 · CIK: 1595353

Galmed Pharmaceuticals LTD. 6-K Filing Summary
FieldDetail
CompanyGalmed Pharmaceuticals LTD. (GLMD)
Form Type6-K
Filed DateJul 24, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: shareholder-meeting, corporate-governance

TL;DR

Galmed calling shareholder meeting Aug 14, expect proxy materials soon.

AI Summary

Galmed Pharmaceuticals Ltd. announced on July 24, 2025, that it will convene a Special General Meeting of Shareholders on August 14, 2025, at 4:00 p.m. Israel time. The meeting will take place at the offices of Meitar | Law Offices in Ramat Gan, Israel. Shareholders will receive a Notice of the Special General Meeting, a Proxy Statement, and a Proxy Card.

Why It Matters

This meeting is a procedural step for Galmed to communicate with its shareholders and potentially vote on important company matters.

Risk Assessment

Risk Level: low — This filing is a routine announcement of a shareholder meeting and does not contain new financial or operational information.

Key Players & Entities

FAQ

When will the Special General Meeting of Shareholders be held?

The Special General Meeting of Shareholders will be held on Thursday, August 14, 2025.

What time is the meeting scheduled for?

The meeting is scheduled for 4:00 p.m. (Israel time).

Where will the meeting take place?

The meeting will take place at the offices of Meitar | Law Offices, located at 16 Abba Hillel Silver Rd., Ramat Gan, 5250608, Israel.

What documents are being provided to shareholders?

Shareholders will receive a Notice of the Special General Meeting of Shareholders, a Proxy Statement, and a Proxy Card.

Is Galmed Pharmaceuticals Ltd. required to file annual reports under Form 20-F or Form 40-F?

Galmed Pharmaceuticals Ltd. indicates it files annual reports under Form 20-F.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on July 24, 2025 regarding Galmed Pharmaceuticals Ltd. (GLMD).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing